Biomarkers in asthma

Current Opinion in Pulmonary Medicine

Volumn 15, Issue 1, 2009, Pages 12-18

  Murugan, Anandhi ^a   Prys Picard, Curig ^a   Calhoun, William J ^a,b  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Asthma; Biomarker; Phenotype; Prediction

Indexed keywords

8 ISOPROSTANE; ACETYLSALICYLIC ACID; ADENOSINE; AMMONIA; ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER; CLARITHROMYCIN; CORTICOSTEROID; CYTOKINE; GELATINASE B; HYDROGEN PEROXIDE; INTERLEUKIN 13; INTERLEUKIN 8; ISOPROSTANE; LEUKOTRIENE E4; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; NEUROKININ A; NITRATE; NITRIC OXIDE; NITRITE; NITROGEN OXIDE; PEPTIDOLEUKOTRIENE; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR; PROSTANOID; SALBUTAMOL; STEROID; UNINDEXED DRUG; UROKINASE;

ASTHMA; BIOINFORMATICS; BREATH ANALYSIS; BRONCHUS BIOPSY; BRONCHUS HYPERREACTIVITY; CELL TYPE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MARKER; DISEASE SEVERITY; DRUG RESPONSE; EOSINOPHIL COUNT; EOSINOPHILIA; EPITHELIUM CELL; EXPIRATORY FLOW; EXPIRED AIR; HEALTH CARE COST; HUMAN; LABORATORY DIAGNOSIS; LABORATORY TEST; LUNG LAVAGE; NEUTROPHIL; NEUTROPHILIA; PH; PREDICTIVE VALIDITY; PROTEIN EXPRESSION; RESPIRATORY EPITHELIUM; RESPIRATORY TRACT INFLAMMATION; REVIEW; SCREENING TEST; SPUTUM ANALYSIS; SUPERNATANT; TRACHEOBRONCHIAL TOILET; TREATMENT RESPONSE; URINALYSIS;

ASTHMA; BIOLOGICAL MARKERS; BREATH TESTS; BRONCHOALVEOLAR LAVAGE; EXHALATION; HUMANS; LEUKOTRIENE E4; NITRIC OXIDE; SPUTUM;

EID: 58149247977     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e32831de235     Document Type: Review

References (74)

1. Dahlén SE, Malmström K, Nizankowska E, et al. Improvement of aspirinintolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165:9-14.
2. Cai C, Yang J, Hu S, et al. Relationship between urinary cysteinyl leukotriene E4 levels and clinical response to antileukotriene treatment in patients with asthma. Lung 2007; 185:105-112.
3. Szefler SJ, Phillips BR, Martinez FD, et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol 2005; 115:233-242.
4. Gustafsson LE, Leone AM, Persson MG, et al. Endogenous nitric oxide is present in the exhaled air of rabbits, guinea pigs and humans. Biochem Biophys Res Commun 1991; 181:852-857.
5. Warke TJ, Fitch PS, Brown V, et al. Exhaled nitric oxide correlates with airway eosinophils in childhood asthma. Thorax 2002; 57:383-387.
6. Massaro AF, Gaston B, Kita D, et al. Expired nitric oxide levels during treatment of acute asthma. Am J Respir Crit Care Med 1995; 152:800-803.
7. Kharitonov SA, Yates D, Robbins RA, et al. Increased nitric oxide in exhaled air of asthmatic patients. Lancet 1994; 343:133-135.
8. Kharitonov SA, Yates DH, Barnes PJ. Inhaled glucocorticoids decrease nitric oxide in exhaled air of asthmatic patients. Am J Respir Crit Care Med 1996; 153:454-457.
9. Smith AD, Cowan JO, Brassett KP, et al. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 2005; 352:2163-2173.
10. Suresh V, Shelley DA, Shin HW, George SC. Effect of heterogeneous ventilation and nitric oxide production on exhaled nitric oxide profiles. J Appl Physiol 2008; 104:1743-1752.
11. Shin HW, Condorelli P, George SC. Examining axial diffusion of nitric oxide in the lungs using heliox and breath hold. J Appl Physiol 2006; 100:623-630.
12. Condorelli P, Shin HW, Aledia AS, et al. A simple technique to characterize proximal and peripheral nitric oxide exchange using constant flow exhalations and an axial diffusion model. J Appl Physiol 2007; 102:417-425.
13. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med 2005; 171:912-930.
14. Covar RA, Szefler SJ, Martin RJ, et al. Relations between exhaled nitric oxide and measures of disease activity among children with mild-to-moderate asthma. J Pediatr 2003; 142:469-475.
15. Komakula S, Khatri S, Mermis J, et al. Body mass index is associated with reduced exhaled nitric oxide and higher exhaled 8-isoprostanes in asthmatics. Respir Res 2007; 8:32-41.
16. Dressel H, de la Motte D, Reichert J, et al. Exhaled nitric oxide: independent effects of atopy, smoking, respiratory tract infection, gender and height. Respir Med 2008; 102:962-969.
17. Kovesi T, Kulka R, Dales R. Exhaled nitric oxide concentration is affected by age, height, and race in healthy 9- to 12-year-old children. Chest 2008; 133:169-175.
18. Kharitonov SA, Gonio F, Kelly C, et al. Reproducibility of exhaled nitric oxide measurements in healthy and asthmatic adults and children. Eur Respir J 2003; 21:433-438.
19. Smith AD, Cowan JO, Filsell S, et al. Diagnosing asthma: comparisons between exhaled nitric oxide measurements and conventional tests. Am J Respir Crit Care Med 2004; 169:473-478.
20. Bommarito L, Migliore E, Bugiani M, et al. Exhaled nitric oxide in a population sample of adults. Respiration 2008; 75:386-392.
21. Porsbjerg C, Brannan JD, Anderson SD, Backer V. Relationship between airway responsiveness to mannitol and to methacholine and markers of airway inflammation, peak flow variability and quality of life in asthma patients. Clin Exp Allergy 2008; 38:43-50. Mannitol challenge is faster and easier to perform than methacholine challenge, and its performance characteristics, ease of administration, and correlation with important asthma outcomes may lead to broader adoption in clinical practice.
22. Moore WC, Bleecker ER, Curran-Everett D, et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol 2007; 119:405-413. This work is the definitive description of severe asthma, as collected by the US Severe Asthma Research program, and includes demographic, physiologic, and immunologic characterizations of these subjects.
23. Pijnenburg MW, Bakker EM, Hop WC, De Jongste JC. Titrating steroids on exhaled nitric oxide in children with asthma: a randomized controlled trial. Am J Respir Crit Care Med 2005; 172:831-836.
24. Pijnenburg MW, Hofhuis W, Hop WC, De Jongste JC. Exhaled nitric oxide predicts asthma relapse in children with clinical asthma remission. Thorax 2005; 60:215-218.
25. Paro-Heitor ML, Bussamra MH, Saraiva-Romanholo BM, et al. Exhaled nitric oxide for monitoring childhood asthma inflammation compared to sputum analysis, serum interleukins and pulmonary function. Pediatr Pulmonol 2008; 43:134-141. For clinicians, the question will often be 'what is the best test at this time?', and this paper outlines the comparative benefits of ENO versus other methods for assessing airway inflammation.
26. Harkins MS, Fiato KL, Iwamoto GK. Exhaled nitric oxide predicts asthma exacerbation. J Asthma 2004; 41:471-476.
27. Pijnenburg MW, Floor SE, Hop WC, De Jongste JC. Daily ambulatory exhaled nitric oxide measurements in asthma. Pediatr Allergy Immunol 2006; 17:189-193.
28. Baptist AP, Shah B, Wang Y, et al. Exhaled nitric oxide levels during treatment in patients hospitalized with asthma. Allergy Asthma Proc 2008; 29:171-176.
29. Shaw DE, Berry MA, Thomas M, et al. The use of exhaled nitric oxide to guide asthma management: a randomized controlled trial. Am J Respir Crit Care Med 2007; 176:231-237. Biomarker based adjustment of asthma therapy may provide important benefits to patients, including better asthma control, or similar asthma control with less inhaled steroid dose. The validity of the application of the findings from clinical trials to 'real world' clinical care has yet to be fully established, but the biomarker based strategies appear to hold promise.
30. Moeller A, Lehmann A, Knauer N, et al. Effects of montelukast on subjective and objective outcome measures in preschool asthmatic children. Pediatr Pulmonol 2008; 43:179-186.
31. Kostikas K, Papaioannou Al, Tanou K, et al. Portable exhaled nitric oxide as a screening tool for asthma in young adults during pollen season. Chest 2008; 133:906-913.
32. Czebe K, Barta I, Antus B, et al. Influence of condensing equipment and temperature on exhaled breath condensate pH, total protein and leukotriene concentrations. Respir Med 2008; 102:720-725. There is great a priori appeal of exhaled breath condensate analysis, due to its sampling of the lower airway, its simple, noninvasive collection, and applicability in a wide range of age. This paper highlights some of the critical technical aspects, which must be controlled to achieve reproducible, and clinically useful results.
33. S Huszar E, Szabo Z, Jakab A, et al. Comparative measurement of thromboxane A2 metabolites in exhaled breath condensate by different immunoassays. Inflamm Res 2005; 54:350-355.
34. Kullmann T, Barta I, Lazar Z, et al. Exhaled breath condensate pH standardised for C02 partial pressure. Eur Respir J 2007; 29:496-501.
35. Kullmann T, Barta I, Antus B, et al. Environmental temperature and relative humidity influence exhaled breath condensate pH. Eur Respir J 2008; 31:474-475.
36. Huszar E, Vass G, Vizi E, et al. Adenosine in exhaled breath condensate in healthy volunteers and in patients with asthma Eur Respir J 2002; 20:1393-1398.
37. Emelyanov A, Fedoseev G, Abulimity A, et al. Elevated concentrations of exhaled hydrogen peroxide in asthmatic patients. Chest 2001; 120:1136-1139.
38. Louhelainen N, Rytila P, Obase Y, et al. The value of sputum 8-isoprostane in detecting oxidative stress in mild asthma. J Asthma 2008; 45:149-154.
39. Ganas K, Loukides S, Papatheodorou G, et al. Total nitrite/nitrate in expired breath condensate of patients with asthma. Respir Med 2001; 95:649-654.
40. Accordino R, Visentin A, Bordin A, et al. Long-term repeatability of exhaled breath condensate pH in asthma. Respir Med 2008; 102:377-381.
41. Kostikas K, Papatheodorou G, Psathakis K, et al. Prostaglandin E2 in the expired breath condensate of patients with asthma. Eur Respir J 2003; 22:743-747.
42. Kostikas K, Gaga M, Papatheodorou G, et al. Leukotriene B4 in exhaled breath condensate and sputum supernatant in patients with COPD and asthma. Chest 2005; 127:1553-1559.
43. Ono E, Mita H, Taniguchi M, et al. Increase in inflammatory mediator concentrations in exhaled breath condensate after allergen inhalation. J Allergy Clin Immunol 2008; 122:768-773. [Epub ahead of print] This paper provides important proof-of-concept information about the biologic performance if exhaled breath condensate measurements, which would be expected to increase during increased inflammation. The information here is one additional piece of the overall validation dataset for exhaled breath condensate measurements.
44. Zanconato S, Carraro S, Corradi M, et al. Leukotrienes and 8-isoprostane in exhaled breath condensate of children with stable and unstable asthma. J Allergy Clin Immunol 2004; 113:257-263.
45. Robroeks CM, van de Kant KD, Jobsis Q, et al. Exhaled nitric oxide and biomarkers in exhaled breath condensate indicate the presence, severity and control of childhood asthma. Clin Exp Allergy 2007; 37:1303-1311. A variety of biomarkers individually associate loosely with clinical measures of asthma control in childhood. Combinatorial analyses of these metrics may offer even better specificity and predictive value.
46. Jackson AS, Sandrini A, Campbell C, et al. Comparison of biomarkers in exhaled breath condensate and bronchoalveolar lavage. Am J Respir Crit Care Med 2007; 175:222-227. No two methods for quantifying lower airway inflammation will be entirely concordant; this work outlines the strengths and limitations of two common testing methods, important for future research in this area. When two methods fail to correlate, the unanswered question is whether one (or both) measures are flawed, or whether the two metrics measure different aspects of disease. There are important implications of this work for design and conduct of future translational and clinical trials.
47. Bayley DL, Abusriwil H, Ahmad A, Stockley RA. Validation of assays for inflammatory mediators in exhaled breath condensate. Eur Respir J 2008; 31:943-948.
48. Koutsokera A, Loukides S, Gourgoulianis Kl, Kostikas K. Biomarkers in the exhaled breath condensate of healthy adults: mapping the path towards reference values. Curr Med Chem 2008; 15:620-630.
49. Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008; 178:218-224. This is another paper that demonstrates that the use of advanced analytic techniques, coupled with accurate clinical phenotyping can provide important information relevant to the classification of asthma. The results of such approaches are dependent on the population studied, but as additional analyses are conducted, recurrent themes emerge that can be tested prospectively.
50. Haldar P, Pavord ID. Noneosinophilic asthma: a distinct clinical and pathologic phenotype. J Allergy Clin Immunol 2007; 119:1043-1052.
51. Cowley HC, Chung KF, Djukanovic R, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airwayhyper- responsiveness, and the late asthmatic response. Lancet 2000; 356:2144-2148.
52. Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360:1715-1721.
53. Jayaram L, Pizzichini MM, Cook RJ, et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J 2006; 27:483-494.
54. Leckie MJ, ten Brinke A, Khan J, et al. Predictors for failed dose reduction of inhaled corticosteroids in childhood asthma. Respirology 2008; 13:400-407. For clinicians, the downward adjustment of inhaled steroid therapy is currently unguided save for the appearance of clinical stability. This paper examines clinically usable metrics that correlate with clinical decompensation consequent to inhaled steroid reduction.
55. Mehta V, Campeau NG, Kita H, Hagan JB. Blood and sputum eosinophil levels in asthma and their relationship to sinus computed tomographic findings. Mayo Clin Proc 2008; 83:671-678.
56. Barck C, Lundahl J, Hallden G, Bylin G. Total eosinophil cationic protein levels in induced sputum as a marker of changes in eosinophilic inflammation in a patient with allergic asthma. Ann Allergy Asthma Immunol 2005; 95:86-92.
57. Simpson JL, Powell H, Boyle MJ, et al. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med 2008; 177:148-155. Refractory asthma is a component of the severe asthma phenotype, and may be associated with neutrophilic, rather than eosinophilic inflammation. This novel therapeutic strategy appears to ameliorate inflammation, and may hold more broad benefit in asthma management.
58. Kowal K, Zukowski S, Moniuszko M, Bodzenta-Łukaszyk A. Plasminogen activator inhibitor-1 (PAI-1) and urokinase plasminogen activator (uPA) in sputum of allergic asthma patients. Folia Histochem Cytobiol 2008; 46:193-198. Increasing evidence, both in animals and humans, links the coagulation pathway to some manifestations of asthma pathogenesis. This paper examines the link to two members of this important cascade.
59. Mostafa GA, Reda SM, Abd El-Aziz MM, Ahmed SA. Sputum neurokinin A in Egyptian asthmatic children and adolescents: relation to exacerbation severity. Allergy 2008 [Epub ahead of print]
60. Saha SK, Berry MA, Parker D, et al. Increased sputum and bronchial biopsy IL- 13 expression in severe asthma. J Allergy Clin Immunol 2008; 121:685-691.
61. Kavuru MS, Dweik RA, Thomassen MJ. Role of bronchoscopy in asthma research. Clin Chest Med 1999; 20:153-189.
62. Julius P, Lommatzsch M, Kuepper M, et al. Safety of segmental allergen challenge in human allergic asthma J Allergy Clin Immunol 2008; 121:712-717.
63. Pavord ID, Cox G, Thomson NC, Rubin AS, Corn's PA, Niven RM, et al. Safety and efficacy of bronchial thermoplasty in symptomatic, severe asthma. Am J Respir Crit Care Med 2007.
64. Jarjour NN, Peters SP, Djukanovic R, Calhoun WJ. Investigative use of bronchoscopy in asthma. Am J Respir Crit Care Med 1998; 157:692-697.
65. Holgate ST. Rhinoviruses in the pathogenesis of asthma: the bronchial epithelium as a major disease target. J Allergy Clin Immunol 2006; 118:587-590.
66. Toda M, Tulic MK, Levitt RC, Hamid Q. A calcium-activated chloride channel (HCLCA1) is strongly related to IL-9 expression and mucus production in bronchial epithelium of patients with asthma. J Allergy Clin Immunol 2002; 109:246-250.
67. Gibson PG, Saltos N, Borgas T. Airway mast cells and eosinophils correlate with clinical severity and airway hyperresponsiveness in corticosteroid-treated asthma. J Allergy Clin Immunol 2000; 105:752-759.
68. Eriksson U, Egermann U, Bihl MP, et al. Human bronchial epithelium controls TH2 responses by TH1-induced, nitric oxide-mediated STAT5 dephosphorylation: implications for the pathogenesis of asthma. J Immunol 2005; 175:2715-2720.
69. Hamilton LM, Davies DE, Wilson SJ, et al. The bronchial epithelium in asthma: much more than a passive barrier. Monaldi Arch Chest Dis 2001; 56:48-54.
70. Tillie-Leblond I, de Blic J, Jaubert F, et al. Airway remodeling is correlated with obstruction in children with severe asthma. Allergy 2008; 63:533-541.
71. Laberge S, Pinsonneault S, Ernst P, et al. Phenotype of IL-16-producing cells in bronchial mucosa: evidence for the human eosinophil and mast cell as cellular sources of IL-16 in asthma Int Arch Allergy Immunol 1999; 119:120-125.
72. Bentley AM, Hamid Q, Robinson DS, et al. Prednisolone treatment in asthma. Reduction in the numbers of eosinophils, T cells, tryptase-only positive mast cells, and modulation of IL-4, IL-5, and interferon-gamma cytokine gene expression within the bronchial mucosa. Am J Respir Crit Care Med 1996. 153:551-556.
73. Shannon J, Emst P, Yamauchi Y, et al. Differences in airway cytokine profile in severe asthma compared to moderate asthma. Chest 2008; 133:420-426.
74. Brasier AR, Victor S, Boetticher GD, et al. Molecular Phenotyping of Severe Asthma Using Pattern Recognition of Bronchoalveolar Lavage-Derived Cytokines. J Allergy Clin Immunol 2008; 121:30-37. Using samples from the US Severe Asthma Research Program, and advanced biostatistical modeling, Brasier showed that BAL cytokines predict both asthma severity and bronchial hyperresponsiveness to methacholine. Such biomarkers may be a useful way to provide more accurate phenotyping of asthma; future research may show that these molecular phenotypes predict response to therapy.